Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
about
Profile of efraloctocog alfa and its potential in the treatment of hemophilia A.The immunogenicity of platelet-derived FVIII in hemophilia A mice with or without preexisting anti-FVIII immunityNon-genetic risk factors in haemophilia A inhibitor management - the danger theory and the use of animal models.Inhibitor development in two cousins receiving full-length factor VIII (FVIII) and FVIII-Fc fusion protein.From IgG Fusion Proteins to Engineered-Specific Human Regulatory T Cells: A Life of Tolerance.Reduction of Factor VIII Inhibitor Titers During Immune Tolerance Induction With Recombinant Factor VIII-Fc Fusion Protein.
P2860
Design of the INHIBIT trial: preventing inhibitors by avoiding 'danger', prolonging half-life and promoting tolerance.
description
2014 nî lūn-bûn
@nan
2014 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@ast
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@en
type
label
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@ast
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@en
prefLabel
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@ast
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@en
P2860
P1476
Design of the INHIBIT trial: p ...... -life and promoting tolerance.
@en
P2093
Lynn M Malec
Margaret V Ragni
P2860
P304
P356
10.1586/17474086.2014.963550
P577
2014-11-05T00:00:00Z